Compass Therapeutics, Inc. (CMPX) Deep Dive Video

Summary

A well-funded bispecific-antibody oncology underdog with a single survival-data gate in 2026 that could unlock a 2027 launch—or reset the entire equity story.

View CMPX stock page · Read the CMPX research report

Loading the video player…